Bevacizumab (Bev) with or without erlotinib as maintenance therapy, in patients (pts) with metastatic colorectal cancer (mCRC): Exploratory analysis according to KRAS status in the gercor DREAM phase III trial

被引：0

作者：

Samson, Benoit

Tournigand, Christophe

Scheithauer, Werner

Lledo, Gerard

Viret, Frederic

Andre, Thierry

Ramee, Jean Francois

Tubiana-Mathieu, Nicole

Dauba, Jerome

Dupuis, Olivier

Rinaldi, Yves

Mabro, May

Aucoin, Nathalie

Khalil, Ahmed

Latreille, Jean

Louvet, Christophe

Brusquant, David

Bonnetain, Franck

Chibaudel, Benoist

De Gramont, Aimery

机构：

[1] Hop Charles LeMoyne, Quebec City, PQ, Canada

[2] Hop Henri Mondor, F-94010 Creteil, France

[3] Med Univ Vienna, Vienna, Austria

[4] Hop Prive Jean Mermoz, Lyon, France

[5] Inst J Paoli I Calmettes, F-13009 Marseille, France

[6] Hop St Antoine, F-75571 Paris, France

[7] Ctr Catherine Sienne, Nantes, France

[8] CHU Limoges, Limoges, France

[9] Ctr Hosp Layne, Mt De Marsan, France

[10] Clin Victor Hugo, Le Mans, France

[11] Hop Ambroise Pare, Marseille, France

[12] Hop Foch, Suresnes, France

[13] Cite Sante Laval, Laval, PQ, Canada

[14] Hop Tenon, F-75970 Paris, France

[15] Hop Charles LeMoyne, Greenfield Pk, PQ, Canada

[16] Inst Mutualiste Montsouris, Dept Oncol, Paris, France

[17] GERCOR, Paris, France

[18] CHU Besancon, F-25030 Besancon, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 04期

关键词：

D O I：

10.1200/jco.2013.31.4_suppl.448

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448

引用

页数：1

共 50 条

[1] Maintenance therapy with bevacizumab with or without erlotinib in metastatic colorectal cancer (mCRC) according to KRAS: Results of the GERCOR DREAM phase III trial.
Tournigand, Christophe
Chibaudel, Benoist
Samson, Benoit
Scheithauer, Werner
Lledo, Gerard
Viret, Frederic
Andre, Thierry
Ramee, Jean Francois
Tubiana-Mathieu, Nicole
Dauba, Jerome
Dupuis, Olivier
Rinaldi, Yves
Mabro, May
Aucoin, Nathalie
Khalil, Ahmed
Latreille, Jean
Louvet, Christophe
Brusquant, David
Bonnetain, Franck
de Gramont, Aimery
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[2] Bevacizumab (Bev) with or without erlotinib as maintenance therapy, following induction first-line chemotherapy plus Bev, in patients with metastatic colorectal cancer (mCRC): Efficacy and safety results of the international GERCOR DREAM phase III trial
Tournigand, Christophe
Samson, Benoit
Scheithauer, Werner
Lledo, Gerard
Viret, Frederic
Andre, Thierry
Ramee, Jean Francois
Tubiana-Mathieu, Nicole
Dauba, Jerome
Dupuis, Olivier
Rinaldi, Yves
Mabro, May
Aucoin, Nathalie
Khalil, Ahmed
Latreille, Jean
Louvet, Christophe
Brusquant, David
Bonnetain, Franck
Chibaudel, Benoist
De Gramont, Aimery
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[3] Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: results of the GERCOR DREAM phase III trial
Anota, Amelie
Vernerey, Dewi
Tournigand, Christophe
Chibaudel, Benoist
Samson, Benoit
Scheithauer, Werner
Brusquant, David
Andre, Thierry
de Gramont, Aimery
Bonnetain, Franck
QUALITY OF LIFE RESEARCH, 2016, 25 : 112 - 112
[4] A randomized phase III trial on maintenance treatment with bevacizumab (bev) alone or in combination with erlotinib (erlo) after chemotherapy and bev in metastatic colorectal cancer (mCRC)
Johnsson, A.
Frodin, J.
Berglund, A.
Hagman, H.
Sundberg, J.
Bergstrom, D.
Christensen, R. D.
Keldsen, N.
Spindler, K. G.
Jakobsen, A. K. M.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[5] Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.
Anota, Amelie
Vernerey, Dewi
Tournigand, Christophe
Chibaudel, Benoist
Samson, Benoit
Scheithauer, Werner
Brusquant, David
Andre, Thierry
De Gramont, Aimery
Bonnetain, Franck
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[6] Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial
Tournigand, Christophe
Chibaudel, Benoist
Samson, Benoit
Scheithauer, Werner
Vernerey, Dewi
Mesange, Paul
Lledo, Gerard
Viret, Frederic
Ramee, Jean-Francois
Tubiana-Mathieu, Nicole
Dauba, Jerome
Dupuis, Olivier
Rinaldi, Yves
Mabro, May
Aucoin, Nathalie
Latreille, Jean
Bonnetain, Franck
Louvet, Christophe
Larsen, Annette K.
Andre, Thierry
de Gramont, Aimery
LANCET ONCOLOGY, 2015, 16 (15): : 1493 - 1505
[7] Bevacizumab with or without erlotinib as maintenance therapy in patients with metastatic colorectal cancer (GERCOR DREAM; OPTIMOX3): a randomised, open-label, phase 3 trial (vol 16, pg 1493, 2015)
Tournigand, C.
Chibaudel, B.
Samson, B.
LANCET ONCOLOGY, 2015, 16 (16): : E589 - E589
[8] IMPACT OF KRAS STATUS ON SURVIVAL IN PATIENTS (PTS.) WITH METASTATIC COLORECTAL CANCER (MCRC) UNDERGOING BEVACIZUMAB (BEV) CONTAINING CHEMOTHERAPY REGIMEN-ANALYSIS OF THE AIO COLORECTAL CANCER STUDY GROUP
Reinacher-Schick, A. C.
Arnold, D.
Kubicka, S.
Hinke, A.
Hegewisch-Becker, S.
Geissler, M.
Graeven, U.
Schmoll, H.
Schmiegel, W.
Tannapfel, A.
ANNALS OF ONCOLOGY, 2010, 21 : 190 - 190
[9] Phase II study of FOLFOX, bevacizumab and erlotinib as initial therapy for patients with metastatic colorectal cancer (MCRC).
Meyerhardt, J. A.
Stuart, K.
Zhu, A.
Fuchs, C.
Bhargava, P.
Earle, C.
Blaszkowsky, L.
Lawrence, C.
Battu, S.
Ryan, D. P.
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 157S - 157S
[10] A phase II trial of mFOLFOX-bevacizumab (bev) followed by single-agent axitinib (ax) as maintenance therapy for patients (pts) with first-line metastatic colorectal cancer (mCRC).
Joseph, Mathew John
Barnes, Kirk
Blachly, Ronald
Kuzur, Michel E.
Bendell, Johanna C.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)

← 1 2 3 4 5 →